To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
Public ClinicalTrials.gov record NCT01011283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of DACOGEN (Decitabine) for Injection and VIDAZA (Azacitidine) for Injection In Subjects With Intermediate or High Risk Myelodysplastic Syndromes (MDS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
Study identification
- NCT ID
- NCT01011283
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Oct 29, 2014
Started 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Hematology and Oncology Associates | Birmingham | Alabama | 35205 | — |
| Stanford University Cancer Center | Stanford | California | 94305 | — |
| Stockton Hematology Oncology | Stockton | California | 95204 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33619 | — |
| Pasco Pinellas Cancer Center | New Port Richey | Florida | 34652 | — |
| Gulf Coast Oncology | St. Petersburg | Florida | 33705 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Siouxland Haeatology - Oncology Associates | Sioux City | Iowa | 51101 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Sletten Cancer Institute | Great Falls | Montana | 59405 | — |
| Cornell Medical Center | New York | New York | 10021 | — |
| Carolinas Medical Center NorthEast NorthEast Oncology Associates | Concord | North Carolina | 28025 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oncology and Hematology Care | Cincinnati | Ohio | 45242 | — |
| University of Pittsburgh School of Medicine | Pittsburgh | Pennsylvania | 15232 | — |
| Charleston Hematology Oncology Associates | Charleston | South Carolina | 29403 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Gunderson Clinic Ltd. | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01011283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2014 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01011283 live on ClinicalTrials.gov.